The acquisition of biosimilars assets of Viatris significantly strengthens BBL’s position in providing affordable access to patients through its portfolio…
It is also Glenmark’s second clinical candidate targeting an oncology indication Glenmark Pharmaceuticals SA (GPSA), a wholly-owned subsidiary of Glenmark…
